Print
Publish Date : 31-03-2022
Description : ICAR-IVRI has developed three technologies i.e., “Recombinant antigen based sero-diagnosis of Infectious Bronchitis”, “Recombinant antigen based sero-diagnosis of Infectious Bursal Disease (IBD) by indirect ELISA”, & “Recombinant antigen based diagnostic kit for sero - diagnosis of Newcastle disease by Single Serum dilution ELISA”. Recombinant antigen based sero-diagnosis of Infectious Bronchitis is designed to measure the relative levels of antibody to IBV in chicken serum. A micro titration format has been developed in which a recombinant protein derived from IBV is coated onto each well. The antibody specific to IBV forms a complex with the coated virus antigen. After washing away unbound materials from the wells, anti-chicken horseradish peroxidase (HRP) is added and colour development occurs in presence of substrate. The assay is useful to assess the immune status of vaccinated birds and the management of large flocks. Recombinant antigen based sero-diagnosis of Infectious Bursal Disease (IBD) by indirect ELISA is a new class of diagnostic tools which could replace the conventional methods based on whole-cell antigens. This ensures that there is no risk involved for both the producer and the user in the handling of live organisms. The recombinant antigen developed in this technology is specific for all the strains of infectious bursal disease virus. Moreover, it is useful to assess the immune status of vaccinated birds and the management of large flocks. The assay can monitor the efficacy of live and killed IBD vaccines. The kit is available in the form of recombinant antigen-coated ELISA plates with a shelf life of 6 months under refrigerated conditions. Patent Number 277404 for the recombinant antigen that was used to develop a single serum dilution ELISA for the serodiagnosis of IBD. Recombinant antigen based diagnostic kit for sero - diagnosis of Newcastle disease by Single Serum dilution ELISA is useful to assess the immune status of vaccinated birds and the management of large flocks. It can monitor the efficacy of live and killed vaccines.
Agrinnovate Commercialized technology of ICAR-IVRI -Recombinant Antigen Based Sero-Diagnosis of Infectious Bronchitis; Recombinant Antigen Based Sero-Diagnosis of Infectious Bursal Disease (IBD) by Indirect ELISA; and Recombinant Antigen Based Diagnostic Kit for Sero-Diagnosis of Newcastle Disease by Single Serum Dilution ELISA
Publish Date : 31-03-2022
Description : ICAR-IVRI has developed three technologies i.e., “Recombinant antigen based sero-diagnosis of Infectious Bronchitis”, “Recombinant antigen based sero-diagnosis of Infectious Bursal Disease (IBD) by indirect ELISA”, & “Recombinant antigen based diagnostic kit for sero - diagnosis of Newcastle disease by Single Serum dilution ELISA”. Recombinant antigen based sero-diagnosis of Infectious Bronchitis is designed to measure the relative levels of antibody to IBV in chicken serum. A micro titration format has been developed in which a recombinant protein derived from IBV is coated onto each well. The antibody specific to IBV forms a complex with the coated virus antigen. After washing away unbound materials from the wells, anti-chicken horseradish peroxidase (HRP) is added and colour development occurs in presence of substrate. The assay is useful to assess the immune status of vaccinated birds and the management of large flocks. Recombinant antigen based sero-diagnosis of Infectious Bursal Disease (IBD) by indirect ELISA is a new class of diagnostic tools which could replace the conventional methods based on whole-cell antigens. This ensures that there is no risk involved for both the producer and the user in the handling of live organisms. The recombinant antigen developed in this technology is specific for all the strains of infectious bursal disease virus. Moreover, it is useful to assess the immune status of vaccinated birds and the management of large flocks. The assay can monitor the efficacy of live and killed IBD vaccines. The kit is available in the form of recombinant antigen-coated ELISA plates with a shelf life of 6 months under refrigerated conditions. Patent Number 277404 for the recombinant antigen that was used to develop a single serum dilution ELISA for the serodiagnosis of IBD. Recombinant antigen based diagnostic kit for sero - diagnosis of Newcastle disease by Single Serum dilution ELISA is useful to assess the immune status of vaccinated birds and the management of large flocks. It can monitor the efficacy of live and killed vaccines.